Vasculitis & polymyalgia rheumatica
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission
Authors' conclusion
Patients with AAV treated with rituximab achieved remission less frequently when concentrations of sLag-3 were low and concentrations of sCD27 were high. Higher concentrations of sTim-3, sCD27 and sBTLA at baseline predicted relapse in patients treated with rituximab.
Study context
- Population
- Patients with AAV (PR3- or MPO-ANCA vasculitis) in the RAVE trial with available baseline plasma samplesplasma samples at baseline
- Participants
- 189 plasma samples
- Comparison
- Baseline soluble immune checkpoint concentrations vs treatment failure, relapse and infections; rituximab vs cyclophosphamide/azathioprine induction
- MPO-ANCAn = 62
- PR3-ANCAn = 127reference
- Rituximabn = 95
- Cyclophosphamide/azathioprinen = 94
Methodological detailsbiomarker study
- Biomarker study
Primary result
As reported in the abstract
Rituximab, remission at 6 months: relapsed during follow-up
24 of 73
32.9%
Original publication
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission. Ann Rheum Dis. Published 16 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →